In addition, although it remains to be determined which of the JBT19-reactive effector cells could deliver the cytotoxic impact, our data also revealed that these JBT19-reactive immune cells were largely expressing LAIR-1 which suggests that the efficacy of their anti-JBT19 cytotoxic activities could be challenged in vivo in the high-content collagen JBT19 tumors, either via collagen itself or in association with other LAIR-1 agonists expressed in the tumor microenvironment. The gene discussed is LAIR1; the disease is neoplasm.